A Phase II Trial of LY317615 in Patients With Recurrent High-Grade Gliomas
Phase 2
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Malignant Glioma
Both
Malignant Glioma
Trial Information
A Phase II Trial of LY317615 in Patients With Recurrent High-Grade Gliomas
Inclusion Criteria:
- You must be at least 18 years old
- You must have been diagnosed with a recurrent brain tumor by MRI or CT scan
- You must be able to swallow the LY317615 tablets
Exclusion Criteria:
- You are a woman who is pregnant or breastfeeding
- In view of your doctor, you have significant heart, liver, kidney, or psychiatric
disease
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To establish data regarding the anti-tumor activity of LY317615 in patients with recurrent high-grade gliomas.
Principal Investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Investigator Role:
Study Director
Investigator Affiliation:
Eli Lilly and Company
Authority:
United States: Food and Drug Administration
Study ID:
5799
NCT ID:
NCT00190723
Start Date:
October 2002
Completion Date:
December 2006
Related Keywords:
- Malignant Glioma
- Glioma
Name | Location |
|---|---|
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician | Bethesda, Maryland 20892 |
